Table 2.
Clinical and demographic baseline characteristics of study participants.
| Transmasculine (TM) group | Transfeminine (TF) group | ||
|---|---|---|---|
| Sample size in total cohort | 11 | 7 | |
| Age a | Mean (SD) | 21.3 (2.5) | 28.0 (5.6) |
| Alcohol (consumptions per week) | Mean (SD) | 0.4 (0.6) | 0.8 (1.9) |
| Smoking (n, %) | Never | 8 (72 %) | 7 (100 %) |
| Previous | 2 (18 %) | 0 (0 %) | |
| Current | 1 (9 %) | 0 (0 %) | |
| Psychotropic medication use at baseline (n, %) | Antidepressants | 2 (18 %) | 1 (14.2 %) |
| Anxiolytics | 0 (0 %) | 0 (0 %) | |
| Stimulants | 2 (18 %) | 0 (0 %) | |
| Antipsychotics | 0 (0 %) | 0 (0 %) | |
| Perceived Stress Score at baseline | Mean (SD) | 12.9 (6.8) | 12.6 (8.8) |
| Cycle regulation use at baseline (n, %) b | 4 (36 %) | – | |
| Form of testosterone prescribed at start of GAHT (n, %) | Testosterone gel | 8 (73 %) | – |
| Short-acting injections | 3 (27 %) | – | |
| Long-acting injections | 0 (0 %) | – | |
| Form of estrogen prescribed at start of GAHT (n, %) | Estradiol tablets | – | 6 (86 %) |
| Estradiol patches | – | 1 (14 %) | |
| Form of anti-androgens prescribed at start of GAHT (n, %) |
GnRH analogues | – | 7 (100 %) |
a
The transmasculine group was significantly younger than the transfeminine group (p = 0.018).
b
2 participants used intramuscular medroxyprogesterone injections, 1 used lynestrenol tablets, 1 had a medroxyprogesterone implant.